Silence: Additional siRNA Drug Data Leads To Next Stages Of Development

andresr/E+ via Getty Images The last time I wrote about Silence Therapeutics plc (NASDAQ:SLN) it was in a Seeking Alpha article entitled "Silence Therapeutics: PV Data For Consideration After ASCVD Treatment Results." With this article, I noted that the company had already released positive results using one of its small interfering RNA [siRNA] candidates, known as zerlasiran. This is for the treatment of patients with elevated levels of Lp[a] at high risk of atherosclerotic cardiovascular disease [ASCVD]. ...